Arbutus Biopharma (ABUS) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Arbutus Biopharma is set to release its third quarter 2024 financial results and provide a corporate update on November 6, 2024. The company continues to advance its promising therapeutics for chronic hepatitis B, with key treatments in various stages of clinical trials. Investors and stakeholders can anticipate insights into the progress of their innovative RNAi therapeutic and PD-L1 inhibitor.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
